NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee on behalf of all persons or entities who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance Therapeutics” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or m ...

ATLANTA, Jan. 06, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about Revance’s business, operations, and prospects, including allegations that: (i) Revance was in material breach of its distribution agreement with Teoxane SA; (ii) the foregoing subjected Revance to ...

Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (Nasdaq: RVNC) to acquire Revance for $3.60 per share in cash. Teoxane beneficially owns 6.2% of the outstanding shares of common stock of Revance. Teoxane's proposal provides a 16% premium over the $3.10 per share price in Rev ...

文章核心观点 - 透明质酸市场近年来显著增长，主要由其在制药、化妆品和食品等行业的多样化应用推动 透明质酸是一种天然存在的多糖，以其出色的保湿能力而闻名，使其成为护肤品中的抢手成分 此外，其在医疗应用中的使用，如骨关节炎治疗和眼科手术，也推动了市场的发展 [2] 市场规模 - 截至2023年，全球透明质酸市场估值约为90亿美元，预计2024年至2029年的复合年增长率（CAGR）约为7%，到2029年将达到约130亿美元 增长因素包括消费者对护肤意识的提高、老龄化人口的增加以及对微创美容手术的需求增长 [3] 产品类型 - 透明质酸市场可分为多种产品类型，包括高分子量（HMW）透明质酸、低分子量（LMW）透明质酸和水解透明质酸 其中，HMW透明质酸在2023年占据了最大的市场份额，主要用于皮肤填充剂和化妆品 而LMW透明质酸因其渗透性在护肤品配方中的应用而受到关注 [4] 关键玩家 - 透明质酸市场的竞争格局包括Allergan、Galderma、Revance Therapeutics、Hyaluronic Acid Manufacturing Co.和Fidia Farmaceutici等主要公司 这些公司专注于产品创新和战略合作伙伴关系，以加强其市场地位 [5] 制造过程 - 透明质酸市场可根据制造过程分为动物组织提取和微生物发酵 微生物发酵预计将主导市场，因其成本效益和与动物源产品相关的疾病传播风险降低 [6] 应用 - 透明质酸市场按应用分为皮肤病学、骨科、眼科和其他领域 皮肤病学领域预计将占据最大的市场份额，主要由于护肤和抗衰老产品的普及 [7][8] 终端用途 - 透明质酸的终端用途行业包括制药、个人护理与化妆品以及食品与饮料 个人护理和化妆品行业预计将见证显著增长，主要由对美容和抗衰老产品的需求增加驱动 [9] 地区 - 北美在2023年占据了最大的市场份额，主要由于主要参与者的存在和消费者意识高 然而，亚太地区预计在预测期内将显示出最高的增长率，主要由可支配收入的增加和对先进美容手术的需求驱动 [10] 市场新闻 - 近年来，透明质酸市场经历了多次政策变化和进展 监管机构如FDA加强了对透明质酸产品的指导，特别是在化妆品应用方面 此外，公司越来越多地投资于研发，以创造创新的产品配方，满足消费者需求 [11] - Allergan最近推出了一系列利用创新交联技术的新型皮肤填充剂，延长了产品的寿命 此外，Galderma扩大了其透明质酸产品组合，包括专门为亚洲皮肤类型配制的产品，进入了有利可图的亚洲市场 [12] 市场预测 - 根据广泛的市场分析，透明质酸市场的以下预测是预期的： - 产品类型：LMW细分市场预计将以9%的CAGR增长，主要由于在化妆品和制药应用中的需求增加 [13] - 应用：皮肤病学细分市场预计将保持最大的市场份额，到2029年达到约55亿美元 [13] - 地区：亚太市场预计将以10%的CAGR增长，主要由于新兴市场消费者意识的提高 [13] 主要供应商 - 全球透明质酸市场的主要供应商包括Anika Therapeutics、Allergan、Genzyme、Shiseido、Seikagaku、Novozymes、Contipro、Galderma、LG、Humedix、SciVision、Bloomage、Shanghai Qisheng、Beijing Mengborun、Haohai Biological、Titan Biotech和BioPlus Co. [16][17]

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.71%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.36, delivering a surprise of 25%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or o ...

Exhibit 99.1 REVANCE Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update – On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the deadline upon which the tender offer must commence to November 12, 2024. The tender offer has not yet commenced. – Revance entered into an amendment to the Exclusive Distribution Agreement with Teoxane for the distributi ...

Revance Therapeutics, Inc. (RVNC) has been on a downward spiral lately with significant selling pressure. After declining 18% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting wh ...

Shares of Revance Therapeutics, Inc. (RVNC) have gained 74.1% over the past four weeks to close the last trading session at $6.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.20 indicates a potential upside of 55%. The average comprises eight short-term price targets ranging from a low of $6.60 to a high of $25, with a standard deviation of $6.30. While the lowest estima ...

MILWAUKEE, Aug. 15, 2024 /PRNewswire/ -- Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation https://www.ademilaw.com/case/revance-therapeutics-inc-0 or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Revance stockholders will receive only $6.66 per share in cash, representing a total enterprise value of $924 million. The transac ...